Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

US-based biotechnology company Genentech, a subsidiary of Roche, has entered into a settlement agreement with Samsung Bioepis, ending all patent litigation between the two companies.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novartis scores UK win in high-stakes Entresto fight

14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.

Pharma

Lilly mounts defence as generics circle Mounjaro and Zepbound

11 August 2026 A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.

Pharma

Reading Stief, Haedicke and Wünsche, with the memory of a decade fought in Germany

10 August 2026 Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.

More features

Former USPTO acting director takes the helm at C4IP

Europe’s missing biotech bridge: Why IP ownership matters more than capital access

Novartis scores UK win in high-stakes Entresto fight

Invisalign maker secures first China win against clear aligner rival

Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie

The ‘Triple Point’ professional: Why patent success requires science, law, and technology

Exclusive: ‘In the end, I did it my own way’ and became a UPC judge

Lilly mounts defence as generics circle Mounjaro and Zepbound

Genentech and Samsung Bioepis settle patent dispute over cancer biosimilar

More on this story

Editor's picks

Editor's picks

More features